Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group

Arrhythmia Service, St. Francis Hospital, Roslyn, New York 11576, USA.

OBJECTIVES. We sought to determine the response rate and safety of intravenous amiodarone in patients with ventricular tachyarrhythmias refractory to standard therapies. BACKGROUND. Numerous small retrospective reports suggest a response of refractory ventricular tachyarrhythmias to intravenous amiodarone, yet no controlled prospective trials exist. METHODS. Two hundred seventy-three patients with recurrent hypotensive ventricular tachyarrhythmias refractory to lidocaine, procainamide and bretylium were randomized to receive one of three doses of intravenous amiodarone: 525, 1,050 or 2,100 mg/24 h (mean [+/- SE] dose 743.7 +/- 418.7, 1,175.2 +/- 483.7, 1,921.2 +/- 688.8 mg, respectively) by continuous infusion over 24 h. RESULTS. Of the 273 patients, 110 (40.3% response rate) survived 24 h without another hypotensive ventricular tachyarrhythmic event while being treated with intravenous amiodarone as a single agent (primary end point). A significant difference in the time to first recurrence of ventricular tachyarrhythmia (post hoc analysis) over the first 12 h was observed when the combined 1,050- and 2,100-mg dose groups were compared with the 525-mg dose group (p = 0.046). The number of supplemental (150 mg) infusions of intravenous amiodarone (given for breakthrough destabilizing tachyarrhythmias) during hours 0 to 6 (prespecified secondary end point) was significantly greater in the 525-mg dose group than in the 2,100-mg dose group (1.09 +/- 1.57 vs. 0.51 +/- 0.97, p = 0.0043). However, there was no clear dose-response relation observed in this trial with respect to success rates (primary end point), time to first recurrence of tachyarrhythmia (post hoc analysis) or mortality (secondary end point) over 24 h. CONCLUSIONS. Intravenous amiodarone is a relatively safe therapy for ventricular tachyarrhythmias refractory to other medications.

This article has been cited by other articles:

				D R Tomlinson, P Cherian, T R Betts, and Y Bashir Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg. Med. J., January 1, 2008; 25(1): 15 - 18. [Abstract] [Full Text] [PDF]

				J. H. Levy, K. A. Tanaka, and J. M. Bailey Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2008; 3(2008): 77 - 110. [Full Text]

				M. P. Anstadt and J. E. Lowe Cardiopulmonary Resuscitation Card. Surg. Adult, January 1, 2008; 3(2008): 487 - 506. [Full Text]

				Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]

				Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]

				The International Liaison Committee on Resuscitati The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support Pediatrics, May 1, 2006; 117(5): e955 - e977. [Abstract] [Full Text] [PDF]

				Part 7.2: Management of Cardiac Arrest Circulation, December 13, 2005; 112(24_suppl): IV-58 - IV-66. [Full Text] [PDF]

				Part 4: Advanced Life Support Circulation, November 29, 2005; 112(22_suppl): III-25 - III-54. [Full Text] [PDF]

				Part 6: Pediatric Basic and Advanced Life Support Circulation, November 29, 2005; 112(22_suppl): III-73 - III-90. [Full Text] [PDF]

				U. N. Srivatsa, R. Ebrahimi, A. El-Bialy, and R. Y. Wachsner Electrical Storm: Case Series and Review of Management Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 237 - 246. [Abstract] [PDF]

				A. T. Cheung, S. J. Weiss, J. S. Savino, W. J. Levy, J. G. Augoustides, A. Harrington, and T. J. Gardner Acute circulatory actions of intravenous amiodarone loading in cardiac surgical patients Ann. Thorac. Surg., August 1, 2003; 76(2): 535 - 541. [Abstract] [Full Text] [PDF]

				J. M. Bailey, K. A. Tanaka, and J. H. Levy Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2003; 2(2003): 85 - 118. [Full Text]

				M. P. Anstadt and J. E. Lowe Cardiopulmonary Resuscitation Card. Surg. Adult, January 1, 2003; 2(2003): 471 - 494. [Full Text]

				R. S. Wright, G. S. Reeder, C. A. Herzog, R. C. Albright, B. A. Williams, D. L. Dvorak, W. L. Miller, J. G. Murphy, S. L. Kopecky, and A. S. Jaffe Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination Ann Intern Med, October 1, 2002; 137(7): 563 - 570. [Abstract] [Full Text] [PDF]

				D. J. Callans Management of the Patient Who Has Been Resuscitated From Sudden Cardiac Death Circulation, June 11, 2002; 105(23): 2704 - 2707. [Full Text] [PDF]

				B. N. Singh Antiarrhythmic Drugs in Cardiac Arrest Resuscitation: Intravenous Amiodarone or Intravenous Lidocaine? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2002; 7(2): 61 - 64. [PDF]

				P. Dorian, D. Cass, B. Schwartz, R. Cooper, R. Gelaznikas, and A. Barr Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular Fibrillation N. Engl. J. Med., March 21, 2002; 346(12): 884 - 890. [Abstract] [Full Text] [PDF]

				P. Kulakowski, S. Karczmarewicz, G. Karpinski, M. Soszynska, and L. CeremuzYnski Effects of intravenous amiodarone on ventricular refractoriness, intraventricular conduction, and ventricular tachycardia induction Europace, January 1, 2000; 2(3): 207 - 215. [Abstract] [PDF]

				M. Greene, D. Newman, M. Geist, M. Paquette, D. Heng, and P. Dorian Is electrical storm in ICD patients the sign of a dying heart?: Outcome of patients with clusters of ventricular tachyarrhythmias Europace, January 1, 2000; 2(3): 263 - 269. [Abstract] [PDF]

				S. J. Connolly Evidence-Based Analysis of Amiodarone Efficacy and Safety Circulation, November 9, 1999; 100(19): 2025 - 2034. [Full Text] [PDF]

				T. Guarnieri, S. Nolan, S. O. Gottlieb, A. Dudek, and D. R. Lowry Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the amiodarone reduction in coronary heart (ARCH) trial J. Am. Coll. Cardiol., August 1, 1999; 34(2): 343 - 347. [Abstract] [Full Text] [PDF]

				J. A. Reiffel Intravenous Amiodarone in the Management of Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(4): 199 - 204. [Abstract] [PDF]

				Amiodarone for V Tach Journal Watch Cardiology, March 1, 1996; 1996(301): 11 - 11. [Full Text]